Work

Supplementary Tables 1-3. from SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non–Small Cell Lung Cancer

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table 1. Univariate analysis of SMARCA4 expression in the Director's Challenge Study. Supplementary Table 2. Log-rank analysis of SMARCA4 expression for observation vs adjuvant cisplatin/vinorelbine in NSCLC within the JBR.10 trial. Supplementary Table 3. Univariate analysis of SMARCA4 expression in the JBR.10 trial.

DOI: 10.1158/1078-0432.22459632

Authors: Erica Hlavin Bell, Arup R. Chakraborty, Xiaokui Mo, Ziyan Liu, Konstantin Shilo, Simon Kirste, Petra Stegmaier, Maureen McNulty, Niki Karachaliou, Rafael Rosell, Gerold Bepler, David P. Carbone, Arnab Chakravarti

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361884722

Cites:

Cited by:

Related to: 10